Nicox Ophthalmics, Inc.

Aciex Therapeutics, Inc.

Other

Vistakon Pharmaceuticals, LLC

Cooper Laboratories, Inc.

Ista Pharmaceuticals, Inc.

Bausch & Lomb Pharma Holdings Corp.

Ophthalmic Research Associates, Inc.

Mark Barry Abelson

Matthew Jonathan Chapin

George Edward Minno

Paul Gomes

Jackie Nice

Frans E Janssens

Kirk McMullin

Avner Ingerman

Anton Megens

Richard L Giovanoni

Angel Padilla

George W Ousler, Iii

Akimitsu Makino

Keith Jeffrey Lane

Mathew Jonathan Chapin

George Minno

The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Ophthalmic formulations of cetirizine and methods of use

Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.

Ophthalmic compositions containing alcaftadine

Provided by the present invention are compositions or formulations suitable for application to a patient's eyes which utilizes a topical ophthalmically-acceptable formulation comprising a therapeutically-effective amount of an ophthalmically-active antimicrobial agent, and an ophthalmically-active anti-inflammatory or steroidal agent in combination with physiologic levels of serum electrolytes in an ophthalmic formulation for the treatment of changes in the normal eye condition. The invention also includes methods of treating patient's having an ophthalmic disease, injury or disorder, utilizing the compositions or formulations. Also provided are kits comprising the compositions or formulations and a means of applying the compositions or formulation to the patient's eyes.

Ophthalmic formulations and uses thereof

The invention features novel topical ophthalmic formulations comprising an osmotically active agent and a vasoconstrictor. Suitable osmotically active agents for use in the ophthalmic formulations of the invention include, without limitation, sodium chloride, dextrose, glycerine, sucrose, mannitol, and sorbitol; suitable vasoconstritors include, without limitation, naphazoline and oxymetazoline. Also provided are methods of using the ophthalmic formulations of the invention for the treatment and prevention of eyelid swelling by administering the ophthalmic formulations of the invention to the eye surface of a subject in need thereof.

Method for the treatment and prevention of eyelid swelling

Compositions, kits, and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.

Ocular allergy treatments with alcaftadine

The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis rhinitis, and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

The present invention provides methods for instilling an ophthalmic agent. One embodiment of a method according to the invention includes causing a patient to refrain from blinking for at least a specified period of time so as to effect the substantial break down of the patient's tear film covering the patient's eye and instilling an ophthalmic agent to the patient's eye.

Instillation techniques for ophthalmic agents to enhance treatment effect

Growing community of inventors

Andover, MA, United States of America

Mark Barry Abelson